Coagulant Therapeutics

Coagulant Therapeutics is a private, pre-clinical stage biotech addressing the critical unmet need for pharmaceutical interventions in acute bleeding, a leading cause of preventable death. The company's core asset is CT-001, a proprietary, engineered version of recombinant Factor VIIa (rFVIIa) optimized for greater activity and improved safety. Leveraging a foundational portfolio of over 30 patents acquired from Bayer AG and Maxygen, Coagulant aims to develop first-in-class treatments for indications like postpartum hemorrhage, intracranial hemorrhage, and trauma. The company is positioned in a large, underserved market with significant clinical and commercial potential.

Protein engineering platform focused on optimizing recombinant coagulation factors, specifically Factor VIIa, for enhanced procoagulant activity and improved safety profiles.

The competitive field for acute bleeding drugs is nascent but includes off-label use of existing recombinant Factor VIIa (NovoSeven®) and other procoagulant agents like fibrinogen concentrates. Several biotechs are developing novel hemostatic approaches, but Coagulant's focused engineering of FVIIa and its acquired IP portfolio position it uniquely in this emerging space.